BUZZ-Viridian jumps as thyroid eye disease drug meets late-stage study goal

Reuters12-16

** Drug developer Viridian Therapeutics' shares rise 32.4% to $23.64 premarket ** Company says its drug, veligrotug, helped to significantly relieve symptoms when tested in patients with chronic thyroid eye disease (TED) during a late-stage trial

** TED causes inflammation and damage to the tissues around the eye and is estimated to affect between 90 and 300 per 100,000 people in the U.S.

** Company plans to submit a marketing application for U.S. approval in the second half of 2025

** As of last close, stock down 18% YTD

(Reporting by Christy Santhosh) ((Christy.Santhosh@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment